Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1282 participants.
Also called NCT01606007
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,282 participants
- Sponsor
- Registry
-
NCT01606007 -
2012-000679-18
-
- Main results
- Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin
- Other papers using this trial's data
- Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Mexico, Poland, Puerto Rico, Romania, South Africa, South Korea
- Registry status
- Completed
Technical summary
Registry record NCT01606007. Randomized; triple masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2014-01 (actual). Results posted on 2015-10-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Saxagliptin
- Intervention (Drug)
- Metformin XR
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Placebo matching with Dapagliflozin
- Intervention (Drug)
- Placebo matching with Saxagliptin
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct01606007- Content hash
9627799ccaf9ff0eee33f84e4ec73473d1633032a979bf878e4f07a1d071fc2e